Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Quanli Han"'
Autor:
Lei Huang, Yao Lv, Shasha Guan, Huan Yan, Lu Han, Zhikuan Wang, Quanli Han, Guanghai Dai, Yan Shi
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-23 (2024)
Abstract Aims We previously showed that the nab-paclitaxel plus S-1 (NPS) regimen had promising effects against metastatic pancreatic ducal adenocarcinoma (mPDAC), whose efficacy however could not be precisely predicted by routine biomarkers. This pr
Externí odkaz:
https://doaj.org/article/fd0890b3b637439fae96a32c1777e114
Autor:
Zhiming Zhao, Xiaomo Li, Fei Wang, Yong Xu, Si Liu, Quanli Han, Zhiying Yang, Weiwei Huang, Zhuzeng Yin, Qu Liu, Haidong Tan, Tonghui Ma, Shuang Si, Jia Huang, Hongling Yuan, Wei Li, Rong Liu
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11672-11685 (2023)
Abstract Background Approximately 90% of pancreatic ductal adenocarcinoma (PDAC) cases are driven by the untargetable non‐G12C KRAS mutations, and only a small subset of patients are eligible for FDA‐approved precision therapies. The practice of
Externí odkaz:
https://doaj.org/article/51b379596788480cb0b8b717dbd72b78
Publikováno v:
Chinese Medical Journal, Vol 135, Iss 5, Pp 606-618 (2022)
Abstract. Background:. Gene promoter methylation is a major epigenetic change in cancers, which plays critical roles in carcinogenesis. As a crucial regulator in the early stages of B-cell differentiation and embryonic neurodevelopment, the paired bo
Externí odkaz:
https://doaj.org/article/0c5439b8e3e943d2a4c52b9083305000
Autor:
Shasha Guan, Guochao Deng, Jingjie Sun, Quanli Han, Yao Lv, Tianhui Xue, Lijuan Ding, Tongxin Yang, Niansong Qian, Guanghai Dai
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposePancreatic cancer is an aggressive solid tumor with a severe prognosis. Although tumor biomarkers are often used to identify advanced pancreatic cancer, this is not accurate, and the currently used biomarkers are not indicative of prognosis. T
Externí odkaz:
https://doaj.org/article/7d2b97ac448d4f718e61cb0871b19709
Autor:
Yan Shi, Quanli Han, Huan Yan, Yao Lv, Jing Yuan, Jie Li, Shasha Guan, Zhikuan Wang, Lei Huang, Guanghai Dai
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundIn our previous phase II study, nab-paclitaxel plus S-1 (NPS) showed encouraging objective response rate (ORR) as first-line treatment for advanced pancreatic adenocarcinoma (APAC). This study aimed to evaluate the effectiveness and safety
Externí odkaz:
https://doaj.org/article/ef82c93b9cf2477fb52422bb51d1f797
Autor:
Weitao Zhang, Lu Kong, Hongbin Zhu, Decong Sun, Quanli Han, Bin Yan, Zhi Cui, Weiwei Zhang, Shurong Zhang, Xindan Kang, Guanghai Dai, Niansong Qian, Wenji Yan
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectiveAberrant activation of Wnt/β-catenin signaling contributes to the maintenance of cancer stem cells and chemoresistance in colorectal cancer (CRC). Retinoic acid-induced 2 (RAI2) was proved to be a tumor suppressor in CRC in our previous rep
Externí odkaz:
https://doaj.org/article/6bdca99c37b8454ea282cec77482e863
Publikováno v:
Frontiers in Genetics, Vol 12 (2022)
Lynch syndrome (LS) is a cancer-predisposing genetic disease mediated by pathogenic mutations in DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2. Accumulating evidence demonstrates that there is significant biological heterogeneity across
Externí odkaz:
https://doaj.org/article/d4929be553bd43c199d2fe695807a384
Publikováno v:
Immunotherapy. 15:127-133
Most advanced colorectal cancer patients with proficient DNA mismatch repair or microsatellite stability (MSS) are insensitive to immune checkpoint inhibitor therapy. This report describes a heavily pretreated refractory colon adenocarcinoma patient
Publikováno v:
Ceramics International. 48:18558-18566
Publikováno v:
International Journal of Applied Ceramic Technology.